VA-DISYS
7.4.2021 15:02:11 CEST | Business Wire | Press release
Digital Intelligence Systems, LLC (DISYS) and Signature Consultants, LLC announce today that an agreement was signed for DISYS to acquire the legal entities of Signature, combine operations, and create one of the largest providers of information technology (IT) staffing services in the U.S. With combined annual revenues of $860M, the organization will also be the second largest minority-owned staffing firm in the nation. Both businesses will maintain their respective brands in the marketplace for the foreseeable future.
The combined operations will draw on the resources of more than 7,500 employees and consultants, serving clients from more than 40 offices, eight countries, and four delivery centers worldwide. Together, the IT firm will offer capabilities in staffing and recruiting, managed services programs (MSPs), consulting and project management, and automation support.
The current DISYS CEO, Mahfuz Ahmed, will serve as the CEO of the combined organization. Dr. Jay Cohen, founder and former CEO of Signature, will remain with the new entity to continue his oversight of day-to-day functioning of Signature operations and to focus on the cultural integration of the newly- combined organization. The senior leadership teams of both organizations will also remain intact.
“For DISYS, combining forces with Signature is a great strategic fit for both of our organizations, this brings expanded opportunities as we continue to diversify our account portfolio and puts us within striking distance of becoming a $1B firm,” said Mahfuz Ahmed, DISYS’ CEO. “DISYS and Signature share attributes that create a synergistic whole and we believe our complementary service offering will enable us to reach new levels of growth. We are stronger together and look ahead to a bright future as we continue to set the standard for the staffing and solutions industry.”
Both companies take great pride in sharing similar values, including collaboration, respect, accountability, fairness, and ingenuity, as well as bringing deep expertise to engagements. The combined company will continue to deepen its technical leadership to deliver high quality service and client-driven results.
“DISYS’ strong operations, successful brand, core values, and exceptional industry practices make them an excellent strategic partner for us,” says Dr. Jay Cohen, founder of Signature. “The combination of our two organizations creates a powerful force in the industry, expanding our clients’ access to an even greater array of IT and professional talent and specialized services and providing enhanced opportunities for our consultants and employees to further their skill development and careers.”
The transaction will be funded through debt financing provided by Wells Fargo Bank and The Carlyle Group. Carlyle’s $56 billion Global Credit platform made the investment with capital primarily from its Credit Opportunities franchise. The Credit Opportunities franchise invests in privately negotiated capital solutions primarily for upper middle market borrowers, including both private equity sponsored and family or entrepreneur-owned companies.
Alex Popov, Carlyle’s Head of Illiquid Credit Strategies, said, “We are excited to partner with industry-leading founders at DISYS and Signature, who have built strong, complementary businesses meeting a growing need for IT staffing, and to provide capital to help them better serve clients and support strategic growth objectives.”
“Wells Fargo is proud to continue our longstanding relationship with DISYS and provide a flexible, asset-based lending solution to support this exciting growth,” said Raphael Torres, Managing Director, Wells Fargo Commercial Capital, Staffing Services Group. “We are honored to be part of this next chapter alongside DISYS’s innovative management team and to continue supporting this strong, minority-owned business with their working capital needs.”
Wells Fargo Commercial Capital continues as the asset-based lender for DISYS. Wells Fargo Securities, LLC served as the exclusive financial advisor to Signature Consultants while Deloitte Consulting provided advisory services on behalf of DISYS.
About Digital Intelligence Systems, LLC (DISYS)
DISYS, founded in 1994 and headquartered in McLean, Virginia, is a global managed services and staffing firm with 33 offices and 4 delivery centers worldwide. As a leading global enterprise, DISYS’ experts are thought leaders in the industry, who bring best-in-class expertise to more than 250 Fortune 500 companies. Recognized as a Top 20 Staffing Provider and one of the Largest Staffing Firms in the U.S., as well as a leading Diversity Staffing Firm by Staffing Industry Analysts (SIA), DISYS is also a certified Minority Business Enterprise (MBE) and Top Supplier to 7 of 10 leading global MSPs. With the support of almost 5,000 internal and external (consultant) employees, DISYS specializes in Global Staffing, Application Development Services, Business Intelligence Services, Cloud Enablement Services, Infrastructure Support Services, Enterprise Apps as-a-Service, Automated Testing, and Process Automation. For more information on the company, please visit www.disys.com .
About Signature Consultants, LLC
Headquartered in Fort Lauderdale, Florida, Signature Consultants was established in 1997 with a singular focus: to provide clients and consultants with superior staffing solutions. With 29 locations throughout North America, Signature annually deploys thousands of consultants to support, run and manage their clients’ technology needs. Signature offers IT staffing, consulting, managed solutions, and direct placement services. For more information on the company, please visit https://www.sigconsult.com . Signature Consultants is the parent company to Hunter Hollis and Madison Gunn .
About The Carlyle Group
The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Investment Solutions. With $246 billion of assets under management as of December 31, 2020, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs 1,825 people in 29 offices across five continents. Further information is available at www.carlyle.com . Follow The Carlyle Group on Twitter @OneCarlyle
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005257/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom